|
Nomura maintains a buy rating on Macrotech Developers with a target price of Rs 1,600, citing strong Q2 performance and anticipated 20% YoY pre-sales growth. For BPCL, Nomura raises the target to Rs 380 despite lower results. Nuvama and Jefferies also maintain buy ratings on Federal Bank (target Rs 235) and Sun Pharma (target Rs 2,150), respectively, highlighting strong performance and growth potential.
Category:
News and Media
Certainly, the investors are relating to the possibility as the IPO has been subscribed only 0.5 times in the retail category which is far less participation as compared with recent IPOs where the subscription was even more then 10-20x of the issue.
Category:
News and Media
Corporate earnings, after four consecutive years of healthy double-digit growth, are moderating due to pressures from commodities and fading tailwinds from BFSI asset quality improvements.
Category:
News and Media
All news |
||||||||||||||||||
|